Not provided
Not provided
Not provided
Not provided
Not provided
Vaccine roll out plans increased so timing was no longer feasible
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Alberta | OTHER |
| University of Saskatchewan | OTHER |
| University of Manitoba | OTHER |
Not provided
Not provided
Not provided
The primary objective of this study is to test whether vaccinating adults ≥18 years in Hutterite colonies with mRNA-1273 (Moderna COVID-19) vaccine as compared to control (usual care) can prevent RT-PCR confirmed COVID-19 in non-vaccinated Hutterite members.
Despite the efficacy that has been demonstrated in Phase III randomized controls trials of mRNA COVID-19 vaccines, a critical question that remains unanswered is whether mRNA vaccines lead to herd immunity. The rationale for conducting this study is to learn whether vaccinating adults with a COVID-19 vaccine will prevent COVID-19 infections in non-vaccinated community members. Hutterite communities are unique since they are isolated from towns and cities and also share a number of communal activities, such as eating meals and attending church. Because of their location and practices, the Hutterite colonies give an opportunity to see whether vaccinating some Hutterite members with the COVID vaccine provides protection to the whole group. If the study shows that immunizing some of the population reduces the level of COVID-19 infection for other members of the population, this may be very important in stopping the COVID-19 pandemic and future pandemics.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COVID-19 | Experimental | mRNA-1273 vaccine |
|
| Control | Experimental | Usual care |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| COVID-19 Vaccination | Biological | Dose 1: 0.5 mL at Day 0 Dose 2: 0.5 mL at Day 28 |
|
| Measure | Description | Time Frame |
|---|---|---|
| RT-PCR confirmed COVID-19 among non-vaccinated Hutterite colony members | RT-PCR confirmed from nasal swabs | 12 week period starting after first dose |
| Measure | Description | Time Frame |
|---|---|---|
| RT-PCR confirmed COVID-19 among all Hutterite colony members | RT-PCR confirmed from nasal swabs | 12 week period starting after first dose |
| RT-PCR confirmed COVID-19 in high-risk participants | RT-PCR confirmed from nasal swabs |
Not provided
Group A: Anyone other than the adults aged ≥18 years who are vaccinated
Inclusion Criteria:
Exclusion Criteria:
- There are no exclusion criteria for this category of participants:
Group B: Adults aged 18 years or older, who will be vaccinated as part of the intervention.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mark Loeb | McMaster University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| McMaster University | Hamilton | Ontario | L8S 4K1 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000079263 | Vaccine-Preventable Diseases |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D007239 | Infections |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C000719707 | heterologous prime boost COVID-19 vaccination |
| D000090983 | 2019-nCoV Vaccine mRNA-1273 |
| ID | Term |
|---|---|
| D000087503 | mRNA Vaccines |
| D000087504 | Nucleic Acid-Based Vaccines |
| D014614 | Vaccines, Synthetic |
| D011994 | Recombinant Proteins |
Not provided
Not provided
Randomized Controlled Trial
Not provided
Not provided
Not provided
| Usual care | Other | Participants can receive the COVID-19 whenever they are eligible according to local provincial guidelines. |
|
| 12 week period starting after first dose |
| COVID-19 antibody testing | Blood spot testing of COVID-19 antibodies | Baseline and through study completion, estimated at 4 months |
| Acute respiratory illness | Participant self-report | 12 week period starting after first dose |
| School or work-related absenteeism | Participant self-report | 12 week period starting after first dose |
| Physician visits for respiratory illness | Participant self-report | 12 week period starting after first dose |
| Signs and symptoms of lower respiratory infection and pneumonia | Participant self-report | 12 week period starting after first dose |
| Intensive care admission | Participant self-report | 12 week period starting after first dose |
| Mechanical ventilation | Participant self-report | 12 week period starting after first dose |
| Death | Participant self-report | 12 week period starting after first dose |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
| D000086663 | COVID-19 Vaccines |
| D014765 | Viral Vaccines |
| D000941 | Antigens |
| D001685 | Biological Factors |